115 related articles for article (PubMed ID: 32436883)
1. Interaction of human immunodeficiency virus-1 and human immunodeficiency virus-2 capsid amino acid variants with human tripartite motif 5α protein SPRY domain and its association with pathogenesis.
Ramalingam VV; Subramanian S; Fletcher GJ; Rupali P; Varghese G; Pulimood S; Jeyaseelan L; Nandagopal B; Sridharan G; Kannangai R
Indian J Med Microbiol; 2019; 37(4):574-583. PubMed ID: 32436883
[TBL] [Abstract][Full Text] [Related]
2. Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5α.
Kömürlü S; Bradley M; Smolin N; Imam S; Pauszek RF; Robia SL; Millar D; Nakayama EE; Shioda T; Campbell EM
PLoS One; 2019; 14(3):e0212888. PubMed ID: 30889178
[TBL] [Abstract][Full Text] [Related]
3. The cyclophilin A-binding loop of the capsid regulates the human TRIM5α sensitivity of nonpandemic HIV-1.
Twizerimana AP; Becker D; Zhu S; Luedde T; Gohlke H; Münk C
Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2306374120. PubMed ID: 37983491
[TBL] [Abstract][Full Text] [Related]
4. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Stremlau M; Perron M; Welikala S; Sodroski J
J Virol; 2005 Mar; 79(5):3139-45. PubMed ID: 15709033
[TBL] [Abstract][Full Text] [Related]
5. The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.
Miyamoto T; Nakayama EE; Yokoyama M; Ibe S; Takehara S; Kono K; Yokomaku Y; Pizzato M; Luban J; Sugiura W; Sato H; Shioda T
PLoS One; 2012; 7(10):e47757. PubMed ID: 23094081
[TBL] [Abstract][Full Text] [Related]
6. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
Perez-Caballero D; Hatziioannou T; Yang A; Cowan S; Bieniasz PD
J Virol; 2005 Jul; 79(14):8969-78. PubMed ID: 15994791
[TBL] [Abstract][Full Text] [Related]
7. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
Speelmon EC; Livingston-Rosanoff D; Li SS; Vu Q; Bui J; Geraghty DE; Zhao LP; McElrath MJ
J Virol; 2006 Mar; 80(5):2463-71. PubMed ID: 16474153
[TBL] [Abstract][Full Text] [Related]
8. Recognition of the HIV capsid by the TRIM5α restriction factor is mediated by a subset of pre-existing conformations of the TRIM5α SPRY domain.
Kovalskyy DB; Ivanov DN
Biochemistry; 2014 Mar; 53(9):1466-76. PubMed ID: 24506064
[TBL] [Abstract][Full Text] [Related]
9. TRIM5α Restriction of HIV-1-N74D Viruses in Lymphocytes Is Caused by a Loss of Cyclophilin A Protection.
Selyutina A; Simons LM; Kirby KA; Bulnes-Ramos A; Hu P; Sarafianos SG; Hultquist JF; Diaz-Griffero F
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215956
[TBL] [Abstract][Full Text] [Related]
10. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.
Maillard PV; Zoete V; Michielin O; Trono D
J Biol Chem; 2011 Mar; 286(10):8128-8140. PubMed ID: 21169362
[TBL] [Abstract][Full Text] [Related]
11. Role of TRIM5α RING domain E3 ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, and restriction of simian immunodeficiency virus.
Kim J; Tipper C; Sodroski J
J Virol; 2011 Aug; 85(16):8116-32. PubMed ID: 21680520
[TBL] [Abstract][Full Text] [Related]
12. Rhesus TRIM5α disrupts the HIV-1 capsid at the inter-hexamer interfaces.
Zhao G; Ke D; Vu T; Ahn J; Shah VB; Yang R; Aiken C; Charlton LM; Gronenborn AM; Zhang P
PLoS Pathog; 2011 Mar; 7(3):e1002009. PubMed ID: 21455494
[TBL] [Abstract][Full Text] [Related]
13. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort.
Onyango CO; Leligdowicz A; Yokoyama M; Sato H; Song H; Nakayama EE; Shioda T; de Silva T; Townend J; Jaye A; Whittle H; Rowland-Jones S; Cotten M
Vaccine; 2010 May; 28 Suppl 2():B60-7. PubMed ID: 20510746
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 with gag processing defects activates cGAS sensing.
Sumner RP; Blest H; Lin M; Maluquer de Motes C; Towers GJ
Retrovirology; 2024 May; 21(1):10. PubMed ID: 38778414
[TBL] [Abstract][Full Text] [Related]
15. Stabilized human TRIM5α protects human T cells from HIV-1 infection.
Richardson MW; Guo L; Xin F; Yang X; Riley JL
Mol Ther; 2014 Jun; 22(6):1084-1095. PubMed ID: 24662946
[TBL] [Abstract][Full Text] [Related]
16. Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.
Boswell MT; Rowland-Jones SL
Clin Exp Immunol; 2019 Jun; 196(3):305-317. PubMed ID: 30773620
[TBL] [Abstract][Full Text] [Related]
17. Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study.
Amanya SB; Nyiro B; Waswa F; Obura B; Nakaziba R; Nabulime E; Katabazi AF; Nabatanzi R; Bayiyana A; Mboowa G; Kayongo A; Wayengera M; Sande OJ
Retrovirology; 2020 Jul; 17(1):19. PubMed ID: 32631377
[TBL] [Abstract][Full Text] [Related]
18. A single amino acid of human immunodeficiency virus type 2 capsid protein affects conformation of two external loops and viral sensitivity to TRIM5α.
Miyamoto T; Yokoyama M; Kono K; Shioda T; Sato H; Nakayama EE
PLoS One; 2011; 6(7):e22779. PubMed ID: 21829511
[TBL] [Abstract][Full Text] [Related]
19. The effect of TRIM5 variants on the susceptibility to HIV-1 infection and disease progression in the Polish population.
Bratosiewicz-Wąsik J; Miklasińska-Majdanik M; Wąsik TJ
Ann Hum Genet; 2024 Mar; 88(2):154-170. PubMed ID: 37942942
[TBL] [Abstract][Full Text] [Related]
20. General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.
Wagner JM; Christensen DE; Bhattacharya A; Dawidziak DM; Roganowicz MD; Wan Y; Pumroy RA; Demeler B; Ivanov DN; Ganser-Pornillos BK; Sundquist WI; Pornillos O
J Virol; 2018 Feb; 92(4):. PubMed ID: 29187540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
